When was Venekra launched in China and can it be reimbursed?

Venetoclax was approved by the U.S.FDA on2016year4month11day. In China, venetoclax was approved for marketing by the State Food and Drug Administration on December 4, 2020. Veneclar has been included in medical insurance and can be reimbursed, only for patients with acute myeloid leukemia.

Veneclatis indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Veneclais also indicated in combination with azacitidine, decitabine, or low-dose cytarabine to treat adults 75 years of age or older with newly diagnosed acute myeloid leukemia (AML) or with comorbidities that preclude the use of intensive induction chemotherapy.

Following several oral doses after meals, maximum plasma concentrations of venetoclax are reached 5-8 hours after dosing. The steady-state AUC (area under the curve) of venetoclax increased proportionally over the dose range of 150-800 mg. Take once daily after a low-fat meal400 The mean (standard deviation) steady-state Cmax of mgdose of venetoclax is 2.1±1.1μg/m L, AUC0-24 is 32.8±16.9μg·h/mL. Compared with the fasting state, venetoclax exposure increased 3.4-fold when ingesting a low-fat meal and increased 5.2-fold when ingesting a high-fat meal. When comparing low-fat and high-fat, both Cmax and AUC were increased by 50% when consumed with a high-fat meal. Retail price of generic venetoclax100mg120tablets2More than a thousand6More than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.